Skip to content

Study · Not a test of the peptide alone · 2007

1 result

Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis.

Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P

Oncogene18 Sept 2006Cited by 82 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking IGF-1 LR3.

  1. 01LabNot a test of IGF-1 LR3 aloneIn vitro (cells)Mechanism

    In a matrigel network formation assay, studies with the non-IGFBP-binding IGF-1 analog Long-R3 showed that IGFBP-3 inhibition of vascular network formation is primarily IGF independent.

    In plain wordsIn lab tests on blood vessel cells, studies using Long-R3 showed that IGFBP-3 blocks vessel network formation mostly without IGF.

    Peptide
    IGF-1 LR3
    Outcome
    Not applicableIGF dependence of IGFBP-3 inhibition of network formation
    Study

    humann: not reported in source

    HUVEC network formation assay
    Outcome group
    Receptor activity and mechanism · Cancer

    Source sentences

    Summary
    This action is primarily IGF independent as shown by studies utilizing the non-IGFBP-binding IGF-1 analog Long-R3.
    1 context sentence
    Summary · context
    In vitro, IGFBP-3 inhibited both vascular endothelial growth factor- and IGF-stimulated human umbilical vein endothelial cells vascular network formation in a matrigel assay.

    In this study, IGF-1 LR3 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking IGF-1 LR3.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.